Heinemann, V., Bekaii-Saab, T., Van Cutsem, E., Tabernero, J., Siena, S., Yoshino, T., … Strickler, J. (2023). Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (MOUNTAINEER-03, trial in progress). In ONCOLOGY RESEARCH AND TREATMENT (Vol. 46, pp. 159–160).

Heinemann, V., T. Bekaii-Saab, E. Van Cutsem, J. Tabernero, S. Siena, T. Yoshino, Y. Nakamura, et al. “Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (MOUNTAINEER-03, trial in progress).” In ONCOLOGY RESEARCH AND TREATMENT, 46:159–60, 2023.

Heinemann V, Bekaii-Saab T, Van Cutsem E, Tabernero J, Siena S, Yoshino T, et al. Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (MOUNTAINEER-03, trial in progress). In: ONCOLOGY RESEARCH AND TREATMENT. 2023. p. 159–60.

Heinemann, V., et al. “Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (MOUNTAINEER-03, trial in progress).” ONCOLOGY RESEARCH AND TREATMENT, vol. 46, 2023, pp. 159–60.

Heinemann V, Bekaii-Saab T, Van Cutsem E, Tabernero J, Siena S, Yoshino T, Nakamura Y, Raghav K, Cercek A, Adelberg D, Ramos J, Yang S, Andre T, Strickler J. Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first-line treatment in HER2+metastatic colorectal cancer (MOUNTAINEER-03, trial in progress). ONCOLOGY RESEARCH AND TREATMENT. 2023. p. 159–160.